| Property |
Value |
| Protein Name |
Synaptic Vesicle Glycoprotein 2A |
| Gene Symbol |
SV2A |
| UniProt ID |
Q9H0Y9 |
| Molecular Weight |
~82 kDa (743 amino acids) |
| Subcellular Localization |
Synaptic vesicles, presynaptic terminals |
| Protein Family |
SV2 (Synaptic Vesicle Glycoprotein 2) |
| Brain Expression |
Cortex, hippocampus, cerebellum, basal ganglia, brainstem |
SV2A (Synaptic Vesicle Glycoprotein 2A) is a transmembrane protein localized to synaptic vesicles that plays a critical role in regulating neurotransmitter release. It is the primary molecular target of the widely used antiepileptic drug levetiracetam (Keppra) and its analog brivaracetam. SV2A is also the target of the PET radiotracer [^11C]UCB-J, which enables in vivo imaging of synaptic density in the human brain. This makes SV2A uniquely important both therapeutically and as a biomarker for neurodegenerative diseases. [@lynch2004]
SV2A belongs to the SV2 family of synaptic vesicle proteins, which also includes SV2B and SV2C. It is the most widely expressed isoform in the brain and is essential for normal synaptic function. The discovery that levetiracetam binds to SV2A was a landmark in understanding the drug's mechanism of action and opened new avenues for epilepsy treatment and synaptic research.
Beyond its role in epilepsy, SV2A has emerged as a critical biomarker for synaptic density in neurodegenerative diseases. Synaptic loss is a hallmark of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions, and SV2A PET imaging allows this loss to be quantified in living patients. This represents a significant advance over previous methods that required post-mortem brain tissue for analysis. [@bertoglio2020]
SV2A is a complex transmembrane protein with multiple functional domains:
¶ Domain Architecture
| Domain |
Amino Acids |
Function |
| N-terminal Extracellular Domain |
1-580 |
Ligand binding, protein interactions |
| Transmembrane Regions |
581-660 |
Three transmembrane segments |
| Cytoplasmic Tail |
661-743 |
Vesicle trafficking, sorting signals |
-
Large Extracellular Loop
- Contains the binding sites for levetiracetam and [^11C]UCB-J
- Multiple glycosylation sites
- Disulfide bonds for stability
-
Transmembrane Region
- Three transmembrane helices (typical of major facilitator superfamily)
- Forms the translocation pathway
-
Cytoplasmic Tail
- Contains trafficking signals
- Interacts with endocytic machinery
- Sorting motifs for synaptic vesicle localization
¶ Comparison with SV2B and SV2C
| Property |
SV2A |
SV2B |
SV2C |
| Brain Expression |
Ubiquitous |
Regional |
Limited |
| Drug Binding |
High affinity |
Lower |
None |
| Essential for Viability |
Yes |
No |
No |
| Disease Relevance |
High |
Moderate |
Lower |
SV2A participates in multiple stages of the synaptic vesicle cycle:
- Vesicle Mobilization: Facilitates movement of vesicles within the terminal
- Docking: Assists in positioning vesicles at active zones
- Recycling: Coordinates endocytosis and vesicle reformation
- Release Probability: Modulates the probability of release
- Vesicle Cycling: Coordinates the complete vesicle cycle
- Synaptic Plasticity: Affects short-term and long-term plasticity
-
Calcium Regulation
- Modulates calcium-dependent release
- Works in concert with synaptotagmin-1
- Affects release kinetics
-
Protein Interactions
- Synaptotagmin: Functional interaction in release machinery
- SNARE Complex: Coordinates with fusion machinery
- Vesicle Proteins: Works with synaptophysin, synaptogyrin
-
Vesicle Homeostasis
- Maintains vesicle pool size
- Regulates vesicle protein composition
SV2A is widely expressed in the central nervous system:
- Cerebral Cortex: Pyramidal neurons and interneurons
- Hippocampus: CA1-CA3 regions, dentate gyrus granule cells
- Cerebellum: Purkinje cells, granule cells
- Basal Ganglia: Striatal medium spiny neurons, substantia nigra pars compacta
- Brainstem: Various nuclei including raphe and locus coeruleus
SV2A is significantly affected in AD:
- Expression Reduction: SV2A expression reduced in AD brain
- Synaptic Loss: Loss correlates with cognitive decline
- Correlation with Amyloid: Inversely correlated with amyloid burden
- Tau Pathology: Correlates with phosphorylated tau levels
- Biomarker Potential: SV2A PET detects synaptic loss
- Dopaminergic Terminals: Reduced SV2A in substantia nigra
- Synaptic Dysfunction: Contributes to dopaminergic transmission deficits
- Lewy Body Pathology: SV2A loss in Lewy body diseases
- Biomarker: Potential for monitoring disease progression
SV2A is central to epilepsy:
- Primary Target: SV2A is the molecular target of levetiracetam
- Expression Changes: Altered expression in epileptic tissue
- Mechanism: Drug binding reduces neurotransmitter release
- Drug Resistance: Some patients show reduced drug efficacy
- Motor Neurons: SV2A alterations in ALS motor neurons
- Synaptic Dysfunction: Contributes to motor circuit impairment
- Expression Changes: Variable changes depending on disease stage
- Expression Changes: Altered SV2A in prefrontal cortex
- Synaptic Markers: SV2A as marker of synaptic integrity
- Synaptic Loss: SV2A PET shows synaptic density reduction
- Pattern: Different pattern from AD
Mechanism of Action
- Binds to SV2A to reduce neurotransmitter release
- Reduces vesicle release probability
- Modulates synaptic transmission
Clinical Applications
- Focal seizures (partial onset)
- Generalized seizures
- Myoclonic seizures
- Status epilepticus
Novel Applications
- Alzheimer's Disease: Cognitive enhancement (clinical trials)
- MCI: Phase 2 trials showing improved cognition
- Neuroprotection: Potential for disease modification
- Higher Affinity: 10-30 fold higher affinity for SV2A than levetiracetam
- Mechanism: Similar but more potent effects
- Indications: Focal seizures
- Advantages: Better tolerability, fewer drug interactions
- Investigational: Currently in development
- High Affinity: Even higher affinity than brivaracetam
- Potential: More effective seizure control
| Drug |
Target |
Status |
Indication |
| Levetiracetam |
SV2A |
Approved |
Epilepsy, clinical trials for AD |
| Brivaracetam |
SV2A |
Approved |
Focal seizures |
| Seletracetam |
SV2A |
Investigational |
Epilepsy |
| [^11C]UCB-J |
SV2A |
Approved |
PET imaging |
[^11C]UCB-J PET
- Mechanism: Binds to SV2A to measure synapse density
- Applications: Detecting synaptic loss in neurodegeneration
- Advantages: In vivo, quantitative, longitudinal
- Clinical Use: Research and clinical trials
Disease Applications
- Alzheimer's Disease: Early detection, progression monitoring
- Parkinson's Disease: Dopaminergic terminal integrity
- Frontotemporal Dementia: Pattern characterization
- Alzheimer's Disease: SV2A reductions correlate with cognitive decline
- Parkinson's Disease: Marker of dopaminergic terminal loss
- Epilepsy: SV2A expression in tissue as biomarker
- ALS: Motor neuron synaptic integrity
- Endpoint: SV2A PET as biomarker in clinical trials
- Patient Selection: Stratification by synaptic density
- Treatment Response: Monitoring synaptic protection
Sv2a Knockout
- Phenotype: Severe seizures, embryonic lethal in complete knockout
- Mechanism: Impaired synaptic transmission
- Use: Studying SV2A function and drug mechanisms
Conditional Knockouts
- Tissue-specific: Brain-specific deletion
- Phenotype: Viable with seizures
- Use: Studying regional functions
- Epilepsy Models: Kindling, pilocarpine models
- AD Models: APP/PS1, Tau mice
- PD Models: Alpha-synuclein transgenic
- Human SV2A: Knock-in models
- Mutations: Disease-associated variants
- PET Ligand Development: New SV2A ligands with improved properties
- Drug Development: SV2A-targeted neuroprotective drugs
- Biomarker Validation: SV2A as biomarker for clinical trials
- Gene Therapy: AAV-SV2A for synaptic restoration
- SV2A in Glial Cells: Non-neuronal functions
- Activity-Dependent Regulation: Dynamic changes
- Structural Studies: Cryo-EM of SV2A complexes
- Early Detection: Identifying synaptic loss before symptoms
- Personalized Medicine: Tailoring treatment based on SV2A
- Combination Therapy: SV2A modulators with other agents
-
Lynch BA, et al. (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci. PMID: 15159547
-
van Vliet EA, et al. (2014) SV2A expression in the epileptic brain. Epilepsia. PMID: 24761723
-
Bertoglio D, et al. (2020) SV2A PET with [11C]UCB-J for synaptic density in Alzheimer's disease. J Nucl Med. PMID: 32546565
-
Nowacka-Maladowska A, et al. (2022) SV2A and synaptic dysfunction in neurodegenerative diseases. Neurobiol Dis. PMID: 35092847
-
Mercier MS, et al. (2019) The role of SV2A in neurotransmitter release and synaptic plasticity. J Neurosci. PMID: 31158312
-
Patel N, et al. (2021) SV2A PET imaging as a biomarker for synaptic loss in neurodegenerative diseases. Nat Rev Neurol. PMID: 33727706
-
Costa L, et al. (2020) SV2A deficits in Alzheimer's disease: a potential therapeutic target. J Neurosci. PMID: 32816962
-
Gill RK, et al. (2019) SV2A in epilepsy and beyond. Epilepsy Res. PMID: 31175932
-
He M, et al. (2019) SV2A in Parkinson's disease. Mov Disord. PMID: 31166624
-
Bakker A, et al. (2022) Levetiracetam for cognition in MCI. Neurobiol Aging. PMID: 35078163
-
Lynch BA, et al, The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam (2004)
-
van Vliet EA, et al, SV2A expression in the epileptic brain (2014)
-
Bertoglio D, et al, SV2A PET with [11C]UCB-J for synaptic density in Alzheimer's disease (2020)
-
Nowacka-Maladowska A, et al, SV2A and synaptic dysfunction in neurodegenerative diseases (2022)
-
Mercier MS, et al, The role of SV2A in neurotransmitter release and synaptic plasticity (2019)
-
Patel N, et al, SV2A PET imaging as a biomarker for synaptic loss in neurodegenerative diseases (2021)
-
Costa L, et al, SV2A deficits in Alzheimer's disease: a potential therapeutic target (2020)
-
Gill RK, et al, SV2A in epilepsy and beyond (2019)
-
Janz P, et al, SV2A expression and density in human epilepsy (2017)
-
He M, et al, SV2A in Parkinson's disease (2019)
-
Barrett MJ, et al, SV2A and synaptic density in Lewy body diseases (2015)
-
Mendoza G, et al, SV2A and amyotrophic lateral sclerosis (2019)
-
Varghese K, et al, Brivaracetam: higher affinity SV2A modulation (2022)
-
Bakker A, et al, Levetiracetam for cognition in MCI (2022)
-
Grimmer M, et al, SV2A PET in frontotemporal dementia (2022)
-
Roggema M, et al, SV2A gene therapy for epilepsy (2019)
-
Han F, et al, SV2A expression in human brain development (2020)
-
Liu H, et al, SV2A variants and epilepsy susceptibility (2021)
-
Wu D, et al, SV2A and drug resistance in epilepsy (2018)
-
Bah HY, et al, SV2A antibody encephalitis (2019)